Innovative range of Hyaluronic Acid, recombinant albumin and enzymes for biocatalysis to be presented alongside insight into China investment
NOTTINGHAM, UK – For the first time, Novozymes Biopharma, part of Novozymes A/S, a world leader in bioinnovation, will showcase its biological-based ingredients and technologies at CPhI China. The company's Hyasis™, Recombumin® and biocatalysis products will feature at the pharmaceutical ingredients event, taking place in Shanghai from June 24 – 27 2013.
Importantly, visitors will also have the chance to hear Amber Deng Yue, Regional Marketing Manager for Novozymes Biopharma, present an introduction to the company and its continued investment in operations in China.
"Hyaluronic acid and albumin have significant roles to play in the future of drug development, both in the Chinese market and worldwide," comments Hemant Pachnanda, business development director at Novozymes Biopharma. "As the world's first and only supplier of animal-free recombinant albumins, Recombumin® Prime and Recombumin® Alpha, we work closely with our partners to deliver safe, stable formulations. Recombumin® leads the market in excipients for liquid drug and vaccine formulations, and users can be sure of superior cGMP quality, regulatory support and long-term supply."
Hyasis® is the next generation of high-quality hyaluronic acid, based on the safe bacteria Bacillus subtilis. Superior heat stability and rapid dissolving time, together with exceptional bath-to-batch consistency characterize the product. Hyasis® expands the number of possible applications of hyaluronic acid in medical device and pharma products. Novozymes' Hyasis can be customized further using the company's proprietary crosslinking technology to achieve a specified viscosity. This enables the product to be adapted for a wide range of drug delivery and medical device applications including ophthalmology, dermal fillers, osteoarthritis, adhesion prevention, coating and wound healing.
Biocatalysis is an enabling technology which can help pharmaceutical and intermediate manufacturers achieve enhanced sustainability performance, energy cost savings, and decreased raw material costs. The range of commercial lipases and proteases can be used in chemical transformations in Active Pharmaceutical Ingredient (API) as well as intermediate manufacturing, offering unique advantages. These include high levels of regioselectivity and stereo selectivity in chemical reactions, reducing the length of the process and the use of expensive, toxic raw materials. The selection of lipases includes Candida Antartica Lipase B (Lipozyme®CALB L), Candida Antartica Lipase A (NovoCor®AD L), immobilized lipases such as Novozym® 435 and proteases like Alcalase® and Savinase®.
The showcase presentations will take place in the Showcase Area in the exhibition hall at the following timings – 10:00-10:20 for Jun 25th and Jun 26th.
To learn more about Novozymes Biopharma and its range of products, please visit stand E1D02 in hall E1 at CPhI China 2013. Alternatively, please visit www.biopharma.novozymes.com.
Novozymes is the world leader in bioinnovation. Together with customers across a broad array of industries, we create tomorrow's industrial biosolutions, improving our customers' business and the use of our planet's resources.
With over 700 products used in 130 countries, Novozymes' bioinnovations improve industrial performance and safeguard the world's resources by offering superior and sustainable solutions for tomorrow's ever-changing marketplace. Read more at www.novozymes.com.
Sally Vernon, Customer Communications Manager
Tel. +44 1159551209